A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009–2016)

Higher-valent pneumococcal conjugate vaccines (PCVs) were licensed from 2009 in Europe; similar worldwide clinical effectiveness was observed for PCVs in routine use. Despite a proven medical need, PCV vaccination in Southern Europe remained suboptimal until 2015/16. We searched PubMed for manuscrip...

Full description

Bibliographic Details
Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Marta Moreira, Olga Castro, Melissa Palmieri, Sofia Efklidou, Stefano Castagna, Bernard Hoet
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-06-01
Subjects:	invasive pneumococcal disease national immunisation programmes pneumococcal conjugate vaccine southern europe vaccination coverage
Online Access:	http://dx.doi.org/10.1080/21645515.2016.1263409

Similar Items

Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme
by: Esra Çakar, et al.
Published: (2025-02-01)

Pneumococcal vaccination coverage in individuals (16–59 years) with a newly diagnosed risk condition in Germany
by: Arijita Deb, et al.
Published: (2022-09-01)

Effect of different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in Vietnamese infants: results from a randomised controlled trialResearch in context
by: Heidi Smith-Vaughan, et al.
Published: (2023-03-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)

EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE: EMERGING DATA FROM INVASIVE PNEUMOCOCCAL DISEASE, PNEUMONIA, ACUTE OTITIS MEDIA AND NASOPHARYNGEAL CARRIAGE
by: Ralf Rene Reinert, et al.
Published: (2012-06-01)

NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD
by: O. P. Kovtun, et al.
Published: (2014-01-01)

Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution
by: Patricia Izurieta, et al.
Published: (2018-06-01)

Global distribution and characteristics of pneumococcal serotypes in adults
by: Haruka Maeda, et al.
Published: (2025-12-01)

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea
by: Deborah Lehmann, et al.
Published: (2017-12-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

Vaccine Prevention of Pneumococcal Infection in Children
by: Alexander A. Baranov, et al.
Published: (2018-07-01)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
by: Earnshaw Stephanie R, et al.
Published: (2012-04-01)

Pneumococcal meningitis trends after pneumococcal conjugate vaccine introduction in Colombia: An interrupted time-series analysis
by: Diana C. Caceres, et al.
Published: (2018-05-01)

The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma
by: Tatiana A. Kaliuzhnaia, et al.
Published: (2020-11-01)

Pneumococcal Vaccination Coverage Among Adults at Risk in the Russian Federation
by: V. A. Korshunov, et al.
Published: (2025-01-01)

Strategies for pneumococcal vaccination in older adults in the coming era
by: Kei Nakashima, et al.
Published: (2024-12-01)

Evolution, Clinical and Microbiological Characteristics of Invasive Pneumococcal Disease since the Introduction of the Pneumococcal Conjugate Vaccine 13-Valent in Adults over 18 Years Old
by: Juan Buades, et al.
Published: (2021-01-01)

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
by: Ann-Charlotte Fridh, et al.
Published: (2024-12-01)

Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States
by: Andrew D. Wiese, et al.
Published: (2019-04-01)

Effectiveness of a Single Dose of Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review
by: Eileen M. Dunne, et al.
Published: (2025-08-01)

Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective
by: Xiuyan Li, et al.
Published: (2023-03-01)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023-09-01)

Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions
by: Jeffrey Vietri, et al.
Published: (2020-01-01)

A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine from Lower-Valent Pneumococcal Conjugate Vaccines in the French Pediatric Population
by: Stéphane Fiévez, et al.
Published: (2025-08-01)

Vaccinal Prevention of Pneumococcal Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

Accelerating Pneumococcal Conjugate Vaccine introductions in Indonesia: key learnings from 2017 to 2022
by: Anithasree Athiyaman, et al.
Published: (2023-11-01)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
by: Mikkelsen Malene B, et al.
Published: (2023-08-01)

Vaccinal Prevention of Lower Respiratory Tract Pneumococcal Disease in Adults Without Immunosuppression
by: I. A. Guchev
Published: (2020-05-01)

The New Era of Pneumococcal Vaccination in Adults: What Is Next?
by: Lale Ozisik
Published: (2025-05-01)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
by: Germaine Hanquet, et al.
Published: (2022-01-01)

Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review
by: Goran Bencina, et al.
Published: (2022-11-01)

Bronchopulmonary Pathology Prevalence Among Premature infants and Estimation of Prophylactic Efficacy and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Premature infants with Bronchopulmonary Dysplasia
by: Vladislav V. Semerikov, et al.
Published: (2020-02-01)

Patterns of basic pneumococcal conjugated vaccine coverage in Ethiopia from 2015 to 2018; further analysis of Ethiopian DHS (2016–2019)
by: Mulugeta Gamachu, et al.
Published: (2024-03-01)

Efficacy of conjugate vaccines in pneumococcal infection prevention
by: A. L. Perova, et al.
Published: (2014-09-01)

Serotype distribution of Streptococcus pneumoniae and potential impact of pneumococcal conjugate vaccines in China: A systematic review and meta-analysis
by: Kaile Chen, et al.
Published: (2018-06-01)

Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017–2018
by: Angel Vila-Córcoles, et al.
Published: (2023-04-01)

A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom
by: James Campling, et al.
Published: (2023-12-01)

Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project
by: Maria Deloria Knoll, et al.
Published: (2021-04-01)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
by: Michael W. Simon, et al.
Published: (2023-08-01)

A decade of 10-valent pneumococcal conjugate vaccine use in Lithuania: trends in invasive pneumococcal serotype dynamics
by: Aurelija Petrutienė, et al.
Published: (2025-08-01)